Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018) · Bone Research · doi:10.1038/s41413-018-0016-9 · Cited by 1,767
“Gene therapy means that treating RA by inserting a gene into a patient’s cells instead of using drugs.(147) Targeting gene therapy in RA is a treatment strategy that is still in very early stages of development but could lead to new possibilities because of treating a disease at its root.”
BackgroundThe next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“Long-term cell replacement afforded by genetically engineered hematopoietic stem cells (HSCs) may durably alleviate a range of conditions, obviating, for example, the need for lifelong enzyme administration or transfusion therapy (3, 4).”
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018) · Cell · doi:10.1016/j.cell.2018.02.033 · Cited by 1,164
“This allows CasRx effector domain fusions to be paired with a CRISPR array encoding multiple guide RNAs while remaining under the packaging size limit of the versatile AAV delivery vehicle (Naldini, 2015) for primary cell and in vivo delivery.”
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
In vitro and ex vivo strategies for intracellular delivery
Stewart, M. P., Sharei, A., Ding, X., Sahay, G., Langer, R., & Jensen, K. F. (2016) · Nature · doi:10.1038/nature19764 · Cited by 885
Qian, X., Zheng, Y., & Chen, Y. (2016) · Advanced Materials · doi:10.1002/adma.201602012 · Cited by 882
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
From haematopoietic stem cells to complex differentiation landscapes
Laurenti, E., & Göttgens, B. (2018) · Nature · doi:10.1038/nature25022 · Cited by 844
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 719
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Elmowafy, E. M., Tiboni, M., & Soliman, M. E. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00439-x · Cited by 621
“Gene therapy interests the researchers of the scientific community by its potential in fighting diseases from their genetic source providing personalized medicine to the patients (Naldini 2015).”
BackgroundExosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs
Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., & Tan, J. (2018) · Advanced Science · doi:10.1002/advs.201700611 · Cited by 625
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
New Generation Cadmium-Free Quantum Dots for Biophotonics and Nanomedicine
Xu, G., Zeng, S., Zhang, B., Swihart, M. T., Yong, K.-T., & Prasad, P. N. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00290 · Cited by 587
DNA Functional Materials Assembled from Branched DNA: Design, Synthesis, and Applications
Dong, Y., Yao, C., Zhu, Y., Yang, L., Luo, D., & Yang, D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00294 · Cited by 533
Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy
Zhang, C., Zeng, Z., Cui, D., He, S., Jiang, Y., Li, J., Huang, J., & Pu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23194-w · Cited by 411
Sun, Y., Lau, S. Y., Lim, Z. W., Chang, S. C., Ghadessy, F., Partridge, A., & Miserez, A. (2022) · Nature Chemistry · doi:10.1038/s41557-021-00854-4 · Cited by 411
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.170 · Cited by 402
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
“…patients bearing mutant modification sites, like K120 mutation in various cancers or R249S mutation in HCC (Liao et al., 2017), gene therapy (like adenovirus-based or CRISPR-Cas9-based gene therapy) may serve as an ideal choice in the future (Naldini, 2015; Wang et al., 2019; Yin et al., 2019).”
BackgroundXu, Y., & Li, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.031 · Cited by 404
Electrospinning: An enabling nanotechnology platform for drug delivery and regenerative medicine
Chen, S., Li, R., Li, X., & Xie, J. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.001 · Cited by 383
“Gene therapy has demonstrated to be safe and therapeutically effective in recent clinical trials [292].”
BackgroundGene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
FGF21 gene therapy as treatment for obesity and insulin resistance
Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., Rodó, J., Mallol, C., Garcia, M., León, X., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708791 · Cited by 324
“Multiple studies have reported high transduction efficiencies for in vivo gene transfer with these vectors, as well as excellent safety profiles in clinical studies (Mingozzi & High, 2011; Naldini, 2015).”
BackgroundSynthetic materials at the forefront of gene delivery
Lostalé-Seijo, I., & Montenegro, J. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0039-1 · Cited by 310
Li, X., Shan, J., Zhang, W., Su, S., Yuwen, L., & Wang, L. (2017) · Small · doi:10.1002/smll.201602660 · Cited by 301
Programming gene and engineered-cell therapies with synthetic biology
Kitada, T., DiAndreth, B., Teague, B., & Weiss, R. (2018) · Science · doi:10.1126/science.aad1067 · Cited by 281
“Although AAV has been used in several recent gene therapy clinical trials (3), the nucleic acid packaging capacity of AAV is only approximately 5 kb (89), which is too small for many of the synthetic gene circuits described above (although AAV codelivery is being investigated).”
BackgroundMethodInfluentialA DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy
Liu, J., Song, L., Liu, S., Jiang, Q., Liu, Q., Li, N., Wang, Z.-G., & Ding, B. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b04812 · Cited by 267
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Refining strategies to translate genome editing to the clinic
Cornu, T. I., Mussolino, C., & Cathomen, T. (2017) · Nature Medicine · doi:10.1038/nm.4313 · Cited by 252
Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9
Batra, R., Nelles, D. A., Pirie, E., Blue, S. M., Marina, R. J., Wang, H., Chaim, I. A., Thomas, J. D., Zhang, N., Nguyen, V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.010 · Cited by 252
“AAVs provide a means to generate therapeutic transgenes such as the RCas9 system for long periods after initial administration but have a limited packaging capacity of 4.7 kb.”
BackgroundInfluentialTorkamani, A., Andersen, K. G., Steinhubl, S. R., & Topol, E. J. (2017) · Cell · doi:10.1016/j.cell.2017.08.007 · Cited by 241
Biasco, L., Pellin, D., Scala, S., Dionisio, F., Basso-Ricci, L., Leonardelli, L., Scaramuzza, S., Baricordi, C., Ferrua, F., Cicalese, M. P., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.04.016 · Cited by 243
Self-citationMcKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M., & Wender, P. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805358115 · Cited by 238
“Specifically, a 1:2 mixture of O11:A9 (3) to N10:A10 (7) was the lead performer in Jurkat cells, demonstrating a sixfold enhancement in expression over D13:A11.”
BackgroundMethodInfluentialNon-viral gene therapy: Gains and challenges of non-invasive administration methods
Foldvari, M., Chen, D. W., Nafissi, N., Calderon, D., Narsineni, L., & Rafiee, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.012 · Cited by 238
“Discussions on affordability of gene therapies indicate the need for improvements in all aspects of development, manufacturability, administration methods and reimbursement models [1, 14, 15].”
BackgroundInfluentialAdvances in stem cell research and therapeutic development
De Luca, M., Aiuti, A., Cossu, G., Parmar, M., Pellegrini, G., & Robey, P. G. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0344-z · Cited by 239
Lesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics
Garcia, S. N., Guedes, R. C., & Marques, M. M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666181213092652 · Cited by 227
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells
Hoban, M. D., Lumaquin, D., Kuo, C. Y., Romero, Z., Long, J., Ho, M., Young, C. S., Mojadidi, M., Fitz-Gibbon, S., Cooper, A. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.148 · Cited by 220
Peptides for nucleic acid delivery
Lehto, T., Ezzat, K., Wood, M. J. A., & EL Andaloussi, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.008 · Cited by 220
Metal–Organic Frameworks (MOF)-Assisted Sonodynamic Therapy in Anticancer Applications
Yang, F., Dong, J., Li, Z., & Wang, Z. (2023) · ACS Nano · doi:10.1021/acsnano.2c10251 · Cited by 217
Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0820 · Cited by 214
“Whereas extensive clinical data show safe, robust, and stable engraftment of LV-modifiedHSCs in several disease settings (36), the specific features of SCID-X1 discussed above may exacerbate any residual risk of insertional mutagenesis and constitutive transgene expression, supporting the potential benefits of a more…”
BackgroundSelf-citationExcision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study
Kaminski, R., Bella, R., Yin, C., Otte, J., Ferrante, P., Gendelman, H. E., Li, H., Booze, R., Gordon, J., Hu, W., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.41 · Cited by 203
Li, X., Xing, L., Zheng, K., Wei, P., Du, L., Shen, M., & Shi, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15185 · Cited by 204
Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models
Chandler, R. J., Sands, M. S., & Venditti, C. P. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.009 · Cited by 203
Viral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
“Several features of retrovirus integration, including tendency to integrate into promoter regions of genes combined with intact (long terminal repeat) LTR elements with enhancer activity in these early vectors have led to improvements in vector design (Naldini, 2015).”
BackgroundPolymer‐Based mRNA Delivery Strategies for Advanced Therapies
Yang, W., Mixich, L., Boonstra, E., & Cabral, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202688 · Cited by 186
Multifunctional MnO2 nanoparticles for tumor microenvironment modulation and cancer therapy
Yang, G., Ji, J., & Liu, Z. (2021) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1720 · Cited by 185
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
Huang, H., Zheng, Y., Chang, M., Song, J., Xia, L., Wu, C., Jia, W., Ren, H., Feng, W., & Chen, Y. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00009 · Cited by 183
Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy
Zhang, Q., Kuang, G., Li, W., Wang, J., Ren, H., & Zhao, Y. (2023) · Nano-Micro Letters · doi:10.1007/s40820-023-01018-4 · Cited by 178
“Currently, gene therapy as an emerging revolutionary treatment technology can specifically regulate and amend the expression of any aberrant gene in cancer cells in theory [10, 11].”
BackgroundAdvances in biological applications of self-assembled DNA tetrahedral nanostructures
Li, S., Tian, T., Zhang, T., Cai, X., & Lin, Y. (2019) · Materials Today · doi:10.1016/j.mattod.2018.08.002 · Cited by 175
Lyu, Y., Cui, D., Sun, H., Miao, Y., Duan, H., & Pu, K. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201705543 · Cited by 175
Zhang, R. X., Ahmed, T., Li, L. Y., Li, J., Abbasi, A. Z., & Wu, X. Y. (2017) · Nanoscale · doi:10.1039/c6nr08486a · Cited by 174
Angiogenic gene therapy in cardiovascular diseases: dream or vision?
Ylä-Herttuala, S., Bridges, C., Katz, M. G., & Korpisalo, P. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw547 · Cited by 173
Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems
Chen, Z., Farag, M. A., Zhong, Z., Zhang, C., Yang, Y., Wang, S., & Wang, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113870 · Cited by 169
Emerging trends in IoT and big data analytics for biomedical and health care technologies
Banerjee, A., Chakraborty, C., Kumar, A., & Biswas, D. (2020) · Handbook of Data Science Approaches for Biomedical Engineering · doi:10.1016/b978-0-12-818318-2.00005-2 · Cited by 148
Nanogels for intracellular delivery of biotherapeutics
Li, D., van Nostrum, C. F., Mastrobattista, E., Vermonden, T., & Hennink, W. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.020 · Cited by 161
“agents for the treatment of various diseases [1,3,51,52].”
Small Heat Shock Proteins, Big Impact on Protein Aggregation in Neurodegenerative Disease
Webster, J. M., Darling, A. L., Uversky, V. N., & Blair, L. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01047 · Cited by 160
“HspB5 interacts with the hydrophobic core of Aβ1-40 and competes for Aβ–Aβ interactions (Narayanan et al., 2006) HspB5 association with Aβ1-40 prevented amyloid fibril-associated cellular toxicity (Dehle et al., 2010).”
Layered double hydroxide nanostructures and nanocomposites for biomedical applications
Yan, L., Gonca, S., Zhu, G., Zhang, W., & Chen, X. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01312a · Cited by 165
Recent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy
Cheng, Y., Li, L., Hu, P., Yang, Y., Wei, W., Deng, X., Wang, L., Tay, F. R., & Ma, J. (2021) · Advanced Science · doi:10.1002/advs.202100540 · Cited by 177
Vargas, J. E., Chicaybam, L., Stein, R. T., Tanuri, A., Delgado-Cañedo, A., & Bonamino, M. H. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1047-x · Cited by 154
“1) and, although some clonal patterns in hematopoietic reconstitutions were suggested, this clonal skewing with transduced cells led to no evident clinical implications [69, 70].”
BackgroundZonari, E., Desantis, G., Petrillo, C., Boccalatte, F. E., Lidonnici, M. R., Kajaste-Rudnitski, A., Aiuti, A., Ferrari, G., Naldini, L., & Gentner, B. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.010 · Cited by 152
“Introduction of the lentiviral vector (LV) platform has spurred applications of gene therapy based on the transplantation of ex-vivo-engineered, autologous hematopoietic stem and progenitor cells (HSPCs) (Naldini, 2015).”
BackgroundSelf-citationConstable, I. J., Pierce, C. M., Lai, C.-M., Magno, A. L., Degli-Esposti, M. A., French, M. A., McAllister, I. L., Butler, S., Barone, S. B., Schwartz, S. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.016 · Cited by 152
Exploiting Advanced Hydrogel Technologies to Address Key Challenges in Regenerative Medicine
Foyt, D. A., Norman, M. D. A., Yu, T. T. L., & Gentleman, E. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700939 · Cited by 150
Arora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149
Cre Recombinase and Other Tyrosine Recombinases
Meinke, G., Bohm, A., Hauber, J., Pisabarro, M. T., & Buchholz, F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00077 · Cited by 171
OM Forum—Healthcare Operations Management: A Snapshot of Emerging Research
Dai, T., & Tayur, S. (2020) · Manufacturing & Service Operations Management · doi:10.1287/msom.2019.0778 · Cited by 147
A Comprehensive Review on Intracellular Delivery
Rad, D. M., Rad, M. A., Bazaz, S. R., Kashaninejad, N., Jin, D., & Warkiani, M. E. (2021) · Advanced Materials · doi:10.1002/adma.202005363 · Cited by 171
Viral Vectors for Gene Transfer
Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146
Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates
Milani, M., Annoni, A., Moalli, F., Liu, T., Cesana, D., Calabria, A., Bartolaccini, S., Biffi, M., Russo, F., Visigalli, I., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7325 · Cited by 142
“On the contrary, HIV-derived lentiviral vectors (LVs) integrate into the target cell chromatin and are maintained as cells divide, a potential advantage for establishing long-term expression if not associated with a significant risk of insertional mutagenesis (6, 7).”
BackgroundSelf-citationZhou, J. J., Sun, L., Wang, L., Liu, Y., Li, J., Li, J., Li, J., & Yang, H. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201813665 · Cited by 142
Triggering antitumoural drug release and gene expression by magnetic hyperthermia
Moros, M., Idiago-López, J., Asín, L., Moreno-Antolín, E., Beola, L., Grazú, V., Fratila, R. M., Gutiérrez, L., & de la Fuente, J. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.004 · Cited by 141
“The main objective of gene therapy is the delivery of foreign genetic material (gene, gene segments or oligonucleotides) into specific cells, with the main aim to treat or alleviate a disease [103].”
BackgroundNanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Adeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
“Unfortunately, the total risk of development of hepatocellular carcinoma secondary to AAV gene therapy in humans is still unknown, but, to date, no genotoxic events have been reported in the >130 rAAV clinical trials conducted so far.(125,126) Kaeppel et al.”
BackgroundZhang, H., Vandesompele, J., Braeckmans, K., Smedt, S. C. D., & Remaut, K. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00194f · Cited by 158
Cebrian-Serrano, A., & Davies, B. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9697-4 · Cited by 154
“Adeno-associated virus (AAV) vectors are one of the most widely used delivery mechanisms for gene therapy (Naldini 2015).”
BackgroundAcid ceramidase deficiency: Farber disease and SMA-PME
Yu, F. P. S., Amintas, S., Levade, T., & Medin, J. A. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0845-z · Cited by 143
“such gene therapy strategies since they are readily accessible and easily separated from a patient’s blood and can expand/ differentiate into long-lived cell types [177, 178].”
BackgroundLipid carriers for mRNA delivery
Zhang, W., Jiang, Y., He, Y., Boucetta, H., Wu, J., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.026 · Cited by 142
“Viral vectors are considered effective carriers to deliver mRNA; however, they are not extensively used due to limitations, such as small packing size, immunogenicity, cytotoxicity, carcinogenesis and production difficulties 28 e 31 .”
Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells
Okada, M., Kanamori, M., Someya, K., Nakatsukasa, H., & Yoshimura, A. (2017) · Epigenetics & Chromatin · doi:10.1186/s13072-017-0129-1 · Cited by 137
“Moreover, lentivirus-mediated gene delivery methods have been established for clinical uses [69].”
ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma
Mao, W., Wang, K., Xu, B., Zhang, H., Sun, S., Hu, Q., Zhang, L., Liu, C., Chen, S., Wu, J., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01443-2 · Cited by 128
“Poly(β-amino ester) s (PBAEs) is an excellent candidate for gene delivery due to its low toxicity and high transfection efficiency [4, 8, 9].”
BackgroundEndocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy
Wang, X., Qiu, Y., Wang, M., Zhang, C.-H., Zhang, T., Zhou, H., Zhao, W., Zhao, W., Xia, G., & Shao, R. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s274289 · Cited by 135
“, take action at genetic roots by counteracting or replacing malfunctioning genes that are involved in cancer-related pathways within the cells.(119) Therefore, targets of gene therapeutics are inside the cells and therapeutic efficacy is reliant on effective cellular internalization.”
BackgroundBak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017) · eLife · doi:10.7554/elife.27873 · Cited by 122
“While these methods have provided great insights into HSPC biology, they come with several confounders, such as random integration of the vector into the host genome, unregulated transgene expression, and incomplete gene knockdown (Woods et al., 2006; Naldini, 2015).”
MethodA concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 141
Engineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 118
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 128
Feng, C., Yuan, X., Chu, K., Zhang, H., Ji, W., & Rui, M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.12.003 · Cited by 119
A new age of precision gene therapy
Schambach, A., Buchholz, C. J., Torres-Ruiz, R., Cichutek, K., Morgan, M. A., Trapani, I., & Büning, H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01952-9 · Cited by 145
dos Santos Rodrigues, B., Oue, H., Banerjee, A., Kanekiyo, T., & Singh, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.043 · Cited by 116
In vivo genome editing via the HITI method as a tool for gene therapy
Suzuki, K., & Belmonte, J. C. I. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0352-4 · Cited by 131
“In fact, clinical trial using this technology have revealed remarkable therapeutic benefits [1].”
Homotypic Targeting Delivery of siRNA with Artificial Cancer Cells
Zhang, L., Deng, S., Zhang, Y., Peng, Q., Li, H., Wang, P., Fu, X., Lei, X., Qin, A., & Yu, X. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201900772 · Cited by 121
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.